In Reply We are grateful for the broad interest in our article.1 In our study, we sought to estimate the percentage of US patients with cancer who are eligible for and may benefit from US Food and Drug Administration (FDA)–approved genome-driven cancer therapies, assuming universal testing and access to these therapies. We found that, as of 2018, the percentage of patients eligible for genome-directed therapies was 8.33%, and the percentage of patients benefiting (ie, those whose response may be attributed to the drug) was 4.90%. These percentages increased linearly at approximately 0.5% annually between 2006 and 2018 (as shown in eFigure 1 in the Supplement of our study).1 We emphasized the need to pursue research on genomic treatment alongside broader therapeutic strategies, such as immunotherapy and cytotoxic drugs.
Marquart J, Chen EY, Prasad V. Moving Precision Oncology Forward Amid Myths and Misconceptions—Reply. JAMA Oncol. 2018;4(12):1790. doi:10.1001/jamaoncol.2018.5111
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: